Appendix carcinoid tumor guide graphic: neuroendocrine tumors of the appendix, grades, surgery, and follow-up, from Appendicure

Appendix Carcinoid Tumor: Neuroendocrine Tumors of the Appendix Explained

An appendix carcinoid tumor, now called a neuroendocrine tumor (NET) of the appendix, is the most common tumor of the appendix. Most are small, low grade, and found by surprise after surgery for appendicitis. For most people, removing the appendix is enough treatment. The 2023 guidance from the European Neuroendocrine Tumor Society (ENETS) recommends a second operation mainly when the tumor is larger than 2 centimeters or was not fully removed.

An appendix carcinoid tumor is usually discovered the same way. Someone has an emergency appendectomy, recovers, and then gets a call about the pathology report. The word tumor is frightening, and the report is full of terms like Ki-67 and mesoappendix. We built this page to explain those terms and what the current evidence says about next steps, which for most people is reassuring.

Neuroendocrine tumors of the appendix are not covered by the 2025 PSM Consortium guidelines used on our other appendix cancer pages, because they behave very differently. This page follows the 2023 ENETS guidance paper written specifically for appendiceal NETs, plus the 2025 consensus guideline for neuroendocrine tumors that have spread to the lining of the abdomen. Sources are listed at the bottom.

What an appendix carcinoid tumor is

Neuroendocrine cells are hormone-making cells spread throughout the gut. A neuroendocrine tumor grows from these cells. Doctors used the word carcinoid for decades, and many patients and some reports still do. The World Health Organization (WHO) now uses the term neuroendocrine tumor, or NET. Both names describe the same thing.

According to the ENETS guidance, NETs make up about half or more of all tumors of the appendix. They are found more often in women, and the typical age at diagnosis is between 25 and 40, though they occur at any age, including in children. About 80 percent are found during surgery for acute appendicitis, and more than 90 percent are first diagnosed by the pathologist after the appendix is removed. Most sit at the tip of the appendix, are smaller than 2 centimeters, and are grade 1.

Not the same as goblet cell carcinoid

A different tumor used to be called goblet cell carcinoid. It is now called goblet cell adenocarcinoma, and it is treated as an adenocarcinoma, not as a neuroendocrine tumor. If your report mentions goblet cells, that page applies to you instead. ENETS notes that some older studies mixed the two, which made appendix NETs look more dangerous than they are.

Reading the pathology report for an appendix carcinoid tumor

ENETS recommends a complete report on every appendix NET, whatever its size. These are the findings that guide decisions:

  • Size. The largest diameter, measured under the microscope. This is the most important single factor.
  • Location. Tip, body, or base of the appendix.
  • Grade. Based on the Ki-67 index, the share of tumor cells that are dividing (see the table below).
  • Depth. How far the tumor reaches through the wall, and whether it goes into the mesoappendix, the fatty tissue that holds the appendix’s blood supply. Older guidelines used 3 millimeters of mesoappendix invasion as a cutoff.
  • Vessel and nerve invasion. Whether tumor cells are seen inside blood vessels, lymph vessels, or along nerves.
  • Margins. R0 means the tumor was completely removed. R1 means tumor cells reach the cut edge.
WHO gradeKi-67 indexWhat it means
Grade 1 (G1)Less than 3 percentSlow-growing. More than 80 percent of appendix NETs.
Grade 2 (G2)3 to 20 percentIntermediate.
Grade 3 (G3)More than 20 percentFast-growing. Very rare in the appendix.

Staging an appendix carcinoid tumor

Appendix NETs have their own TNM staging, different from appendix adenocarcinoma. ENETS recommends the 8th edition of the UICC/AJCC system:

T categoryWhat it means
T1Tumor 2 cm or smaller
T2Tumor larger than 2 cm and up to 4 cm
T3Tumor larger than 4 cm, or reaching the subserosa or mesoappendix
T4Tumor breaks through the outer lining (serosa) or grows into nearby organs

ENETS adds an important warning about T4. In an inflamed appendix, the appendicitis itself can cause a perforation. A hole caused by appendicitis should not be reported as a T4 tumor. Only a perforation caused by the tumor counts, and ENETS believes true T4 tumors are probably overcounted.

Tests after an appendix carcinoid tumor diagnosis

Most people with a small, completely removed, low-grade appendix NET need no special scans or blood tests. ENETS says:

  • The blood and urine markers often used for neuroendocrine tumors, chromogranin A (CgA) and 5-HIAA, are of limited value for finding leftover disease after appendectomy.
  • A CT or MRI scan could be considered for higher-risk features, such as a tumor larger than 2 cm or a high grade 2 or grade 3 tumor. MRI is preferred for young patients to limit radiation.
  • A gallium-68 DOTATATE PET/CT scan, a special scan that lights up neuroendocrine cells, can be done if the CT or MRI shows something suspicious.

Carcinoid syndrome, the flushing and diarrhea caused by hormones from some neuroendocrine tumors, is extremely rare with appendix NETs. When it does appear, or when spread to the liver is found, ENETS recommends looking for a second neuroendocrine tumor in the small intestine, which is often the real source.

Treatment for an appendix carcinoid tumor

When removing the appendix is enough

For most people, the appendectomy that found the tumor is the whole treatment. ENETS does not generally recommend more surgery for a tumor 2 cm or smaller that was completely removed. This is a real change from older guidelines, which sent more patients to a second operation based on features like mesoappendix invasion or vessel invasion. Newer studies found that these features did not reliably predict harm.

When a second operation is recommended

ENETS recommends a completion right hemicolectomy, which removes the right side of the colon and nearby lymph nodes, when:

  • The tumor is larger than 2 cm.
  • The tumor was not completely removed (R1 or R2 margins).

For tumors between 1 and 2 cm, a higher grade or the patient’s own wishes may justify a second operation, and those cases should be discussed by a team that specializes in neuroendocrine tumors. ENETS found no clear evidence that a second operation helps when the only concern is a perforated outer lining. A smaller operation called an ileocecal resection can be an alternative, particularly for children and young adults.

The evidence behind this change is worth knowing. Even when patients had a second operation because of high-risk features, ENETS found that at most about a quarter had cancer in their lymph nodes. In recent studies, lymph node involvement in appendix NETs was not linked to a higher chance of the cancer coming back or spreading. A 2025 German study of 82 patients found that 21 of the 27 people who had a guideline-based second operation had no cancer in the lymph nodes or elsewhere, and tumor size over 2 cm was the only factor linked to lymph node spread.

A right hemicolectomy is a real operation. ENETS reports complications in about 5 to 15 percent of people, mostly minor, and some report more diarrhea afterward. That is why the guidance now aims to avoid unnecessary surgery, especially in young people.

Chemotherapy

ENETS does not recommend chemotherapy or other drug treatment after surgery for appendix NETs that have not spread, because almost all are low grade.

When an appendix NET has spread

Spread beyond the lymph nodes is very rare. Across recent studies covering more than 2,000 patients, ENETS counted metastatic disease in about 1 in 200. When it happens, treatment follows the approach used for other gut neuroendocrine tumors. Options can include surgery or other treatments aimed at the liver, long-acting somatostatin analog drugs, targeted drugs, peptide receptor radionuclide therapy (PRRT), and chemotherapy. The right choice depends on grade, how fast the tumor is growing, and how much disease there is.

For neuroendocrine tumors that have spread to the lining of the abdomen, the 2025 PSM Consortium guideline gave strong support to cytoreductive surgery for grade 1 and grade 2 tumors, after any hormone symptoms are controlled. For grade 3 tumors, drug treatment comes first, with surgery considered in select cases. That guideline covers neuroendocrine tumors from any starting site, not only the appendix.

Follow-up after an appendix carcinoid tumor

Follow-up for appendix NETs is lighter than for other appendix cancers. ENETS focuses it on higher-risk cases:

  • After a right hemicolectomy that finds no cancer in the lymph nodes, ENETS says patients can be considered cured and do not need further follow-up.
  • For a tumor larger than 2 cm, or a high grade 2 or grade 3 tumor, the need for follow-up should be discussed by a neuroendocrine tumor team.
  • If lymph nodes contained cancer and there are other high-risk features, follow-up with CT or MRI may be considered, with a gallium-68 DOTATATE PET/CT scan if something shows up.

ENETS notes that there are no proven blood markers for routine follow-up, and that because most patients are young, the radiation from repeated scans should be weighed too.

Add your neuroendocrine tumor data to the registry

The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including neuroendocrine tumor. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.

Already enrolled? Add new reports or correct your record.

Frequently asked questions about appendix carcinoid tumors

Is an appendix carcinoid tumor cancer?

Neuroendocrine tumors are classified as cancers that can spread, but most appendix NETs are small, low grade, and fully treated by removing the appendix. Spread beyond the lymph nodes is very rare.

Do I need a right hemicolectomy for an appendix carcinoid tumor?

Usually not. The 2023 ENETS guidance recommends a right hemicolectomy when the tumor is larger than 2 cm or was not completely removed. It does not generally recommend more surgery for a completely removed tumor 2 cm or smaller.

Do I need chemotherapy for an appendix carcinoid tumor?

No. ENETS does not recommend chemotherapy or other drug treatment after surgery for appendix NETs that have not spread, because almost all are low grade.

Will an appendix carcinoid tumor cause carcinoid syndrome?

Very rarely. Carcinoid syndrome is extremely uncommon with appendix NETs. If it appears, doctors usually look for a second neuroendocrine tumor in the small intestine.

Is goblet cell carcinoid the same as an appendix carcinoid tumor?

No. Goblet cell carcinoid is the old name for goblet cell adenocarcinoma, a different cancer that is treated like an adenocarcinoma, not like a neuroendocrine tumor.

What follow-up do I need after an appendix carcinoid tumor?

ENETS focuses follow-up on higher-risk cases, such as tumors larger than 2 cm, high grade 2 or grade 3 tumors, or cancer in the lymph nodes. Those decisions are best made with a neuroendocrine tumor team. People with no lymph node involvement after a right hemicolectomy can be considered cured.

Sources

  • Kaltsas G, Walter T, Knigge U, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J Neuroendocrinol. 2023;35(10):e13332. doi.org/10.1111/jne.13332
  • Su DG, Brown LM, Bansal VV, et al. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer. 2025;131(13):e35871. doi.org/10.1002/cncr.35871
  • Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi.org/10.1111/his.13975
  • Wächter S, Panidis D, Jesinghaus M, et al. Retrospective analysis of criteria for oncological completion surgery of neuroendocrine tumors of the appendix. Langenbecks Arch Surg. 2025;410(1):46. doi.org/10.1007/s00423-024-03603-6
  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867

Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.